INSERM, CIE3, Université Jean Monnet, EA3065, CHU Saint-Etienne, Service de Médecine et Thérapeutique, Saint-Etienne, F-42055 France.
Thromb Res. 2011 Feb;127 Suppl 3:S81-5. doi: 10.1016/S0049-3848(11)70022-6.
Recent data on lower-limb superficial-vein thrombosis (SVT) may substantially impact its clinical management. Thus, the clear confirmation that SVT is closely linked to deep-vein thrombosis (DVT) or pulmonary embolism (PE) highlights the potential severity of the disease. DVT or PE are diagnosed in 20-30% of SVT patients. Moreover, clinically relevant symptomatic thromboembolic events complicate isolated SVT (without concomitant DVT or PE at diagnosis) in 4-8% of patients. For the first time, an anticoagulant treatment, once-daily 2.5 mg fondaparinux for 45 days, was demonstrated to be effective and safe for preventing these symptomatic thromboembolic events in patients with lower-limb isolated SVT in the randomized placebo-controlled CALISTO study. Based on these recent findings, new recommendations on the management of SVT patients, including complete ultrasonography examination of the legs, and in patients with isolated SVT, prescription of once-daily 2.5 mg fondaparinux subcutaneously for 45 days on top of symptomatic treatments, may be proposed.
近期有关下肢浅静脉血栓形成（SVT）的数据可能会对其临床管理产生重大影响。因此，明确确认 SVT 与深静脉血栓形成（DVT）或肺栓塞（PE）密切相关，突出了该疾病的潜在严重性。在 20-30%的 SVT 患者中诊断出 DVT 或 PE。此外，在无诊断时同时伴有 DVT 或 PE 的孤立性 SVT 患者中，有 4-8%出现临床相关的有症状血栓栓塞事件。在随机安慰剂对照的 CALISTO 研究中，首次证明每日一次 2.5 毫克磺达肝癸钠治疗 45 天可有效且安全地预防这些下肢孤立性 SVT 患者的这些有症状血栓栓塞事件。基于这些最新发现，可能会提出有关 SVT 患者管理的新建议，包括对腿部进行完整的超声检查，以及对于孤立性 SVT 患者，在对症治疗的基础上，每日一次皮下注射 2.5 毫克磺达肝癸钠治疗 45 天。
